Author | Jill Wechsler

Jill Wechsler is BioPharm International's Washington Editor,


Stakeholders Seek Increased User Fee Support for Biologics

July 24, 2020


Patient advocates, research experts, and industry are calling for more user fee revenues to support CBER programs to advance innovative therapies.

Drug Pricing Back in the Spotlight

July 21, 2020


Should therapies and vaccines be cheap or free in a pandemic and would that really dry up innovation?

Will FDA Inspections Ever Be the Same?

July 20, 2020


Industry should be seeking more information from FDA on how it will restart its current inspection program.

FDA Maps Expectations for COVID Vaccine Proposals

July 09, 2020


FDA officials are moving to clarify standards and requirements for vetting and approving viable preventives.